Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Meclocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 14/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.77 |
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | USP2 | O75604 | 8/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.77 |
| ▸ | RECQL | P46063 | 7/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.77 |
| ▸ | HPGD | P15428 | 7/20 | 0.77 |
| ▸ | THRB | P10828 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | LMNA | P02545 | 4/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.77 |
| ▸ | CASP7 | P55210 | 2/20 | 0.77 |
| ▸ | CASP1 | P29466 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meclocycline SCHEMBL5849023 | 1.00 | TDP1 (0.77) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL193563 | 1.00 | TDP1 (0.77) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL28357495 | 0.89 | TDP1 (0.61) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL24321867 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL21133274 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL21133273 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL3445 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL29427550 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL195707 | 0.89 | TDP1 (0.59) | TDP1KDM4EMEN1KMT2AUSP2 | |
| Meclocycline SCHEMBL4207351 | 0.88 | TDP1 (0.58) | TDP1KDM4EMEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260061030-A1 | COMPOSITIONS AND SYNERGISTIC METHODS FOR TREATING INFECTIONS | BIOAEGIS THERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260060920-A1 | DRUG DELIVERY FOR INTERVERTEBRAL DISC PAIN MANAGEMENT | GLOBUS MEDICAL INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260027101-A1 | BACTERIAL TOPOISOMERASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4665724-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | Ohio State Innovation Foundation (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220251160-A1 | IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLES | IRVINE, DARRELL | 2022-08-11 | — | — | US | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220185860-A1 | CELL SURFACE COUPLING OF NANOPARTICLES | IRVINE, DARRELL | 2022-06-16 | — | — | US | disclosed |
| US-11352349-B2 | Type II topoisomerase inhibitors and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220160464-A1 | SMART COMPOSITE WITH ANTIBIOFILM, MINERALIZING, AND ANTIINFECTION THERAPEUTIC EFFECTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3308719-B1 | EXPANDABLE DEVICE FOR TISSUE COLLECTION FROM AN AERODIGESTIVE BODY LUMEN | ADN INT LLC (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3965799-A1 | COMPOSITIONS AND SYNERGISTIC METHODS FOR TREATING INFECTIONS | Bioaegis Therapeutics Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3946489-A1 | SMART COMPOSITE WITH ANTIBIOFILM, MINERALIZING, AND ANTIINFECTION THERAPEUTIC EFFECTS | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022020752-A1 | LIQUID CRYSTAL SCAFFOLDS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027101-A1 | BACTERIAL TOPOISOMERASE INHIBITORS | TOP1, TOP2A, TOP2B | TDP1 124/4885KDM4E 1214/4885MEN1 4743/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | TDP1 944/4885KDM4E 1006/4885MEN1 4544/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | TDP1 256/4885KDM4E 147/4885MEN1 1099/4885 |
| US-20260060920-A1 | DRUG DELIVERY FOR INTERVERTEBRAL DISC PAIN MANAGEMENT | NGF, SBDS, OPRD1 | TDP1 3756/4885KDM4E 1352/4885MEN1 3739/4885 |
| US-11352349-B2 | Type II topoisomerase inhibitors and methods of making and using thereof | TOP2A, TOP1, TOP2B | TDP1 34/4885KDM4E 3359/4885MEN1 4184/4885 |
| US-20220185860-A1 | CELL SURFACE COUPLING OF NANOPARTICLES | EPCAM, CD47, CD63 | TDP1 4094/4885KDM4E 4345/4885MEN1 2736/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | TDP1 1333/4885KDM4E 484/4885MEN1 4294/4885 |
| US-20260061030-A1 | COMPOSITIONS AND SYNERGISTIC METHODS FOR TREATING INFECTIONS | SLC11A2, GSDMD, C5 | TDP1 2754/4885KDM4E 4778/4885MEN1 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.